Colostrum and Gut Health
A Randomized Controlled Trial to Examine the Impact of Two Colostrum Doses on Gut Health
The primary objective of this study is to evaluate changes in participant-reported gastrointestinal function over a 16-week intervention period and a 4-week non-supplementation period (20 weeks total) following daily consumption of two different doses of colostrum in comparison to a placebo.
Secondary objectives include evaluation of digestive comfort, immune resilience, energy levels, sleep quality, hsCRP, metabolic panel, microbiome status and function, and hair and skin health.
Exploratory objectives include the collection of physical activity status and pulse rate variability at specified timepoints to provide supportive contextual information alongside participant-reported outcomes.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This randomized, double-blind, placebo-controlled, fully decentralized study will evaluate the effects of two daily doses of bovine colostrum compared with placebo on gastrointestinal health and related health outcomes in adults. Aadults aged 30 to 60 years will be enrolled and randomized in a 1:1:1 ratio to one of three study groups: one of two bovine colostrum doses or a matched placebo. The study is designed to obtain approximately 105 participants who complete the protocol.
The study will be conducted entirely remotely, with no required in-person study visits. Following electronic screening and informed consent, eligible participants will complete baseline assessments through the Alethios digital research platform. Participants will then consume their assigned study product once daily with food for 16 weeks. The supplementation period will be followed by a 4-week non-supplementation period to evaluate outcomes following discontinuation of the study product. Total participant involvement is expected to be approximately 20 to 21 weeks.
The primary objective is to evaluate changes in participant-reported gastrointestinal function during the 16-week supplementation period. Gastrointestinal function will be assessed using the PROMIS Gastrointestinal (GI) Combined Short Form, with the primary endpoint defined as the change from baseline to Week 16.
Secondary outcomes will evaluate digestive comfort and gut health, perceived immune system strength and resilience, energy levels, sleep quality, metabolic health, gut microbiome status and function, and hair and skin health. Exploratory outcomes will include physical activity and heart rate variability derived from compatible wearable devices or connected health-data sources.
Participant-reported assessments will be completed at scheduled intervals throughout the study, including baseline and Weeks 2, 4, 8, 12, 16, and/or 20, depending on the specific outcome. Digestive comfort/gut health and immune resilience assessments will continue through the 4-week post-supplementation period to characterize changes following discontinuation of the study product.
Participants will also complete at-home biospecimen collections. Dried blood spot samples will be collected to assess metabolic health, including high-sensitivity C-reactive protein (hsCRP), and stool samples will be collected for assessment of gut microbiome status and function. These biospecimens will be collected at baseline and Week 16 and returned to designated analytical laboratories using provided collection and shipping materials. Participants will additionally provide standardized photographs for assessment of hair and skin health.
Study product adherence will be monitored electronically through the study platform. Participants will record study product intake during the supplementation period and will be able to report adverse events or other health concerns throughout the study. Where available, compatible wearable devices or connected Apple Health/Google Fit data sources will be used to passively collect physical activity and heart rate variability data.
The primary analysis will compare longitudinal changes in gastrointestinal function among the three randomized groups. A linear mixed-effects model will be used with supplementation group and time as fixed effects and participant as a random effect. Secondary and exploratory outcomes will be analyzed using statistical methods appropriate to the distribution and longitudinal structure of each outcome.
The study is intended to characterize the effects of daily bovine colostrum supplementation on gastrointestinal function and related consumer health outcomes and to explore whether changes in gastrointestinal health are accompanied by changes in digestive comfort, immune resilience, energy, sleep, metabolic markers, gut microbiome characteristics, hair and skin health, physical activity, and heart rate variability.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Chad Kerksick, PhD
- Numero di telefono: 650-206-8006
- Email: chad.kerksick@gmail.com
Luoghi di studio
-
-
California
-
San Francisco, California, Stati Uniti, 94109
- Alethios, Inc.
-
Contatto:
- Zeenia Framroze, MA
- Numero di telefono: 650-206-8006
- Email: zeenia@alethios.com
-
Contatto:
- Zoe Benham, BS
- Numero di telefono: 650-206-8006
- Email: zoe@alethios.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 30 to 60 years at the time of enrollment.
- Self-reported suboptimal digestive function (e.g., bloating, irregular bowel habits, discomfort) and/or suboptimal immune function (e.g., frequent colds, low energy) during the previous 4 weeks.
- Willing and able to consume a powdered supplement (3-6 g) mixed in liquid once daily.
- Own a compatible iOS or Android smartphone with internet access.
- Willing to connect a compatible wearable device (Apple Watch or Oura Ring) or Apple Health/Google Fit data source for passive data collection.
- Complete at least 30 minutes of physical activity or exercise most days of the week.
- Able to provide informed consent and comply with the study protocol for 20 weeks.
- Able to read and understand English.
- Willing to provide informed consent electronically.
Exclusion Criteria:
- Diagnosis of inflammatory bowel disease, Crohn's disease, ulcerative colitis, or other malabsorptive gastrointestinal disease or condition.
- Diagnosis of celiac disease or known severe allergy to dairy-derived or bovine colostrum products.
- Currently pregnant, breastfeeding, or planning pregnancy during the study period.
- Current or within the previous 30 days use of immunosuppressive medications, systemic corticosteroids, or biologic agents.
- Use of bovine colostrum or colostrum-containing supplements within the previous 30 days.
- Regular use of probiotic or prebiotic supplements within 14 days of enrollment. Does not participate in at least 30 minutes of physical activity or exercise most days of the week.
- Major gastrointestinal surgery within the previous 12 months.
- Autoimmune condition requiring immunomodulatory treatment.
- Participation in another interventional clinical study within 30 days of enrollment.
- Body mass index greater than 35.0 kg/m².
- Known or severe lactose intolerance or milk protein allergy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Lower Dose Bovine Colostrum
Participants randomized to this group will consume the protocol-defined lower dose of bovine colostrum once daily with food for 16 weeks, followed by a 4-week non-supplementation period. |
Participants randomized to this group will consume the protocol-defined lower dose of bovine colostrum once daily with food for 16 weeks, followed by a 4-week non-supplementation period. |
|
Sperimentale: Higher-Dose Bovine Colostrum
Participants randomized to this group will consume the protocol-defined higher dose of bovine colostrum once daily with food for 16 weeks, followed by a 4-week non-supplementation period. |
Participants randomized to this group will consume the protocol-defined higher dose of bovine colostrum once daily with food for 16 weeks, followed by a 4-week non-supplementation period. |
|
Comparatore placebo: Placebo
Participants randomized to this group will consume a matched placebo once daily with food for 16 weeks, followed by a 4-week non-supplementation period. |
Participants randomized to this group will consume a matched placebo once daily with food for 16 weeks, followed by a 4-week non-supplementation period. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Gastrointestinal Function Assessed by the PROMIS Gastrointestinal Combined Short Form
Lasso di tempo: Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20
|
Gastrointestinal function will be assessed using the PROMIS Gastrointestinal Combined Short Form (PROMIS-GI-SF), a self-administered questionnaire assessing dimensions of gastrointestinal status and function. The primary endpoint is the change in gastrointestinal function from baseline to the end of the 16-week supplementation period. |
Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Digestive Comfort and Gut Health
Lasso di tempo: Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20
|
Participants will rate their digestive comfort and gut health by answering the question, "Overall, how would you rate for digestive health and gut comfort today?" Answers are provided using a visual analog scale ranging from 0 (Very Poor) to 100 (Excellent). |
Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20
|
|
Change in Perceived Immune System Strength and Resilience
Lasso di tempo: Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20
|
Participants will rate their immune strength and resilience by answering the question, "How would you rate the overall strength and resilience of your immune system over the past 7 days?" Answers are provided using a visual analog scale ranging from 0 (Very Poor) to 100 (Excellent). |
Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20
|
|
Change in Participant-Reported Energy Levels
Lasso di tempo: Week 0, Week 2, Week 4, Week 8, Week 12, Week 16
|
Participants will rate their energy levels by answering the question, "In the past 7 days, how would you rate your overall energy levels throughout the day?" Answers are provided on a Likert scale ranging from 1 (Very low energy) to 7 (Very high energy). |
Week 0, Week 2, Week 4, Week 8, Week 12, Week 16
|
|
Change in Participant-Reported Sleep Quality
Lasso di tempo: Week 0, Week 2, Week 4, Week 8, Week 12, Week 16
|
Participants will rate their sleep quality by answering the question, "In the past 7 days, how would you rate the quality of your sleep overall?" Answers are provided on a Likert scale ranging from 1 (Very poor sleep) to 7 (Excellent sleep). |
Week 0, Week 2, Week 4, Week 8, Week 12, Week 16
|
|
Change in total cholesterol
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate concentrations of total cholesterol. Units of measure are in milligrams per deciliter. |
Week 0 and Week 16
|
|
Evaluation of baseline and change in microbial diversity
Lasso di tempo: Week 0 and Week 16
|
Participant-collected stool samples will be analyzed to evaluate changes in microbial diversity. Evaluations are made based on detected bacterial taxa and strains. An index (unitless) is provided. |
Week 0 and Week 16
|
|
Change in Hair Strength
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their hair strength by answering the question, "My hair feels more nourished and less dry or brittle? Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Skin Hydration
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their skin hydration by answering the question, "My skin feels hydrated?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in HDL cholesterol
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate concentrations of high-density lipoprotein (HDL) cholesterol. Units of measure are in milligrams per deciliter. |
Week 0 and Week 16
|
|
Change in LDL cholesterol
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate concentrations of low-density lipoprotein (LDL) cholesterol. Units of measure are in milligrams per deciliter. |
Week 0 and Week 16
|
|
Change in high-sensitivity C-reactive protein
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate concentrations of high-sensitivity C-reactive protein (CRP). Units of measure are in milligrams per liter. |
Week 0 and Week 16
|
|
Change in hemoglobin A1c (HbA1c)
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate levels of hemoglobin A1c (HbA1c). Units of measure are in % of total hemoglobin. |
Week 0 and Week 16
|
|
Change in gamma-glutamyl transferase (GGT)
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate concentrations of gamma-glutamyl transferase (GGT). Units of measure are in units per liter. |
Week 0 and Week 16
|
|
Change in fasting glucose
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate fasting concentrations of glucose. Units of measure are in milligrams per deciliter. |
Week 0 and Week 16
|
|
Evaluation of baseline and change in microbial abundance
Lasso di tempo: Week 0 and Week 16
|
Participant-collected stool samples will be analyzed to evaluate changes in microbial abundance. Evaluations are made based on detected bacterial taxa and strains. A percentage or proportion of relative abundance of total bacterial sequences will be quantified. |
Week 0 and Week 16
|
|
Evaluation of baseline and change in microbial richness
Lasso di tempo: Week 0 and Week 16
|
Participant-collected stool samples will be analyzed to evaluate changes in microbial richness. Evaluations are made based on detected bacterial taxa and strains. An index (unitless) is provided. |
Week 0 and Week 16
|
|
Evaluation of baseline and change in microbial evenness
Lasso di tempo: Week 0 and Week 16
|
Participant-collected stool samples will be analyzed to evaluate changes in microbial evenness. Evaluations are made based on detected bacterial taxa and strains. An index (unitless) is provided. |
Week 0 and Week 16
|
|
Evaluation of baseline and change in the amount of short-chain fatty acid producers
Lasso di tempo: Week 0 and Week 16
|
Participant-collected stool samples will be analyzed to evaluate changes in bacterial taxa that are known fatty acid chain producers. General relative abunance (%) will be provided. |
Week 0 and Week 16
|
|
Change in the ratio of triglycerides to HDL cholesterol ratio
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate changs in the ratio of triglycerides to HDL choelsterol. This measurement is a unitless ratio. |
Week 0 and Week 16
|
|
Change in triglycerides
Lasso di tempo: Week 0 and Week 16
|
At-home dried blood spot samples will be collected to evaluate concentrations of triglycerides. Units of measure are in milligrams per deciliter. |
Week 0 and Week 16
|
|
Modified hair pull test
Lasso di tempo: Week 0 and Week 16
|
Participants will complete a modified hair pull test. The number of hair strands yielded from the hair pull test will be counted and used for assessment. |
Week 0 and Week 16
|
|
Change in Hair Quality
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their hair quality by answering the question, "I have noticed an improvement in overall hair quality?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Hair Health
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their hair health by answering the question, "I have noticed an improvement in the appearance of hair health?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Hair Texture
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their hair texture by answering the question, "I have noticed an improvement in hair texture?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Hair Volume
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their hair volume by answering the question, "I have noticed an improvement in hair volume?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Hair Shedding
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their hair shedding by answering the question, "I have noticed an improvement in hair shedding?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Clearness of Skin
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their skin clearness by answering the question, "My skin appears clear?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Overall Skin Health
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their overall skin health by answering the question, "I have noticed an improvement in my overall skin health?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Dry Skin
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their overall skin dryness by answering the question, "I am experiencing dry skin?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
|
Change in Happiness with Skin
Lasso di tempo: Week 0 and Week 16
|
Participants will rate their overall happiness with their skin by answering the question, "I am happy with my skin?" Answers are provided using a 5-point Likert style scale with 1=Strongly Disagree and 5=Strongly Agree. |
Week 0 and Week 16
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Daily Step Count
Lasso di tempo: Baseline through Week 20.
|
Step count data will be passively collected, where available, from compatible wearable devices or connected Apple Health/Google Fit data sources. |
Baseline through Week 20.
|
|
Change in Wearable-Derived Heart Rate Variability
Lasso di tempo: Baseline through Week 20
|
Heart rate variability will be passively collected from compatible wearable devices or connected health-data sources where available |
Baseline through Week 20
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BOV 001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data will not be made publicly available due to participant privacy considerations, the inclusion of multiple potentially sensitive data types, and sponsor data-governance requirements. Aggregate study results may be disseminated through scientific publication and other appropriate channels.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .